WO1985002402A1 - 5-heteroarylimidazol-2-ones - Google Patents

5-heteroarylimidazol-2-ones Download PDF

Info

Publication number
WO1985002402A1
WO1985002402A1 PCT/US1984/001854 US8401854W WO8502402A1 WO 1985002402 A1 WO1985002402 A1 WO 1985002402A1 US 8401854 W US8401854 W US 8401854W WO 8502402 A1 WO8502402 A1 WO 8502402A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
loweralkyl
heteroaryl
compounds
pharmaceutically acceptable
Prior art date
Application number
PCT/US1984/001854
Other languages
French (fr)
Inventor
David M. Stout
Diane M. Yamamoto
Original Assignee
American Hospital Supply Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Hospital Supply Corporation filed Critical American Hospital Supply Corporation
Priority to DE8585900282T priority Critical patent/DE3480475D1/en
Publication of WO1985002402A1 publication Critical patent/WO1985002402A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • Cardiotonic agents have been used for the treatment of heart failure for some time with digitalis continuing to be one of the principle pharmacologic agents used for this purpose, although the cardiac glycosides as a class do have some limitations.
  • the output is regulated by the integration of the contractile state of the heart and the dynamics of the peripheral circu latory system.
  • the primary problem is impairment of ventricular myocardial contractility which results in inadequate cardiac output to meet the metabolic and circulatory demands of the body.
  • Effective therapy of heart failure is accomplished by either enhancing the contractile state of the heart with positive inotropic agents, or by adjusting the peripheral circulatory state with pheripheral vasodilators. Agents which stimulate myocardial contractility are of considerable value in the treatment of heart failure.
  • the present invention is directed to compounds of the formula
  • R is heteroaryl and R' is hydrogen or loweralkyl, and pharmaceutically acceptable salts thereof.
  • loweralkyl refers to straight or branched chain aIkyI radicals containing from 1 to 6 carbon atoms Including but not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, 2-methyIhexyI, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methyIpentyI, 2,2-dimethylpropyl, n-hexyl and the like.
  • heteroaryl includes bicyclic heteroaryl such as phthalazine, quinazoline, quinoline, or isoquinoline, and phenyl, either unsubstituted or substituted, naphthyl, thiazole, thiadiazole, thiophene, or pyridyl.
  • salts includes nontoxic acid addition salts of the compounds of the invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Representative salts include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, paimitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and like salts.
  • metallic salts such as the sodium or potassium salt of the acid.
  • the present compounds may be administered to warm-blooded animals orally or parenterally. They can generally be administered with a pharmaceutical carrier.
  • pharmaceutical carrier for the purpose of the present invention, is intended to refer to any medium that is suitable for the preparation of a dosage unit form, and, thus, includes the tablet medium or a pharmaceuticaly acceptable vehicle or solvent such as is ordinarily used in the preparation of intravenous or intramuscular solutions.
  • a pharmaceutical composition containing the compound can be administered to warm-blooded animals in parenteral or oral dosage form.
  • parenteral administration amounts of from about 10 to 100 mg/kg per day per patient are useful, with the total dose of up to 0.2 to 2 grams per day being a suitable range for large animals, including humans.
  • a preferred dosage range is from about 1 to 10 grams total daily dosage in a single or divided dose.
  • the above exemplified compounds can be placed in capsules, formulated into piIIs, wafers, or tablets in conventional fashion together with pharmaceutical carriers well known in the art. Tablets may be prepared for immediate release of the active compound or they may be made enteric. i.e., whereby the active ingredient is released slowly over a period of several hours from within the intestinal tract.
  • the compounds of the invention can be made by the following described method, the reaction scheme illustrating a representative procedure.
  • Example 2 To the oxlme 2 of Example 2 (5.0 g, 33 mmol) dissolved in pyrldlne (31 mL) was added p-toiuenesulfonyl chloride (7.4 g, 39 mmol) and the reaction mixture stirred at room temperature for 24 hours. Pyridine hydrochloride was removed by filtration and the filtrate concentrated under reduced pressure.
  • the described compounds are active Inotropic or cardiotonic agents. They have been found to increase the contractile force of the heart while having minimal effects on blood pressure and heart rate and can be used in treating patients with diseased hearts for the purpose of increasing cardiac efficiency through a selective increase in the cardiac contractile force.
  • the cardiotonic activity of the compounds was established using the following test procedure: Male Hartley strain guinea pigs (250-500 g body weight), obtained from Hilltop Lab Animals (Scottdale, PA), were stunned by a blow to the head and the left atria removed and rinsed in a modified Kreb's-Henseleit buffer.
  • the buffer was continuously gassed with 95% oxygen and 5% carbon dioxide and was composed of the following: NaCI, 118 mM; KCI, 4.7 mM; MgSO 4 , 1.2 mM; KH 2 PO 4 , 1.2 mM; CaCI 2 , 1.25 mM;
  • the glass rod and atrium were suspended in a 30 ml water-jacketed tissue bath containing the Kreb's buffer at 33° C. Also connected to the glass rod was a second shielded platinum wire which was adjusted so that a 3-5 mm length of an unshielded portion of the wire was in contact with the atrium very near to the first shielded wire. Both platinum wires were connected to a Grass CCU1A constant current unit and a current was applled by a Grass S44 stimulator to drive the atrium by means of "point" stimulation. The parameters of stimulation were 1-3 mAmps, 1.5 Hz and 5 msec pulse duration. Each tissue was stretched to an initial resting tension of 1.0 g without further readjustment and washed periodically with fresh Kreb's buffer over a one-hour interval.
  • test compounds were added cumulatively to the bath in small volumes (10-100 ul) at 10-mlnute intervals beginning at concentrations of 10 -7 M and increasing by log or 1/2 log units until a concentration of 3 x 10 -3 M was reached.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treating Waste Gases (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compounds of formula (I), wherein R is heteroaryl and R1 is hydrogen or loweralkyl, or a pharmaceutically acceptable salt thereof. The compounds exhibit cardiotonic activity.

Description

5-HETEROARYL I MIDAZOL-2-ONES
Background of the Invention
Cardiotonic agents have been used for the treatment of heart failure for some time with digitalis continuing to be one of the principle pharmacologic agents used for this purpose, although the cardiac glycosides as a class do have some limitations. The output is regulated by the integration of the contractile state of the heart and the dynamics of the peripheral circu latory system. When the heart fails, the primary problem is impairment of ventricular myocardial contractility which results in inadequate cardiac output to meet the metabolic and circulatory demands of the body. Effective therapy of heart failure is accomplished by either enhancing the contractile state of the heart with positive inotropic agents, or by adjusting the peripheral circulatory state with pheripheral vasodilators. Agents which stimulate myocardial contractility are of considerable value in the treatment of heart failure. Conventional therapy for heart failure has been the use of digitalis preparations which are the only orally effective inotropic drugs available for use in the treatment of this condition. However, their peripheral vascular effects are undesirable. Sympathomimetic amines are the other major class of cardiac stimulants which are used for the treatment of heart failure. The use of these agents is likewise limited, because they are not fully effective when administered orally and because of undesirable peripheral vasoconstrictor action. Currently, dobutamine and dopamine are the sympathomimetic agents which are primarily used for heart failure. A promising inotropic agent which has been studied recently is the bipyridyl analog amrinone hav ing the following formula:
Figure imgf000004_0001
See Drug's of the Future, A, 245 (1979), and A. E. Parah, et a l, Life Sci . , 21, 1 139 ( 1978) . in pentobarbital induced heart failure in dogs, amrinone caused an increase in both contractile force and cardiac output. However, experiments in dogs with experimentally induced ischemia indicate that amrinone and isoproterenol may increase acute ischemia and myocardial injury which could possibly limit the use of amrinone in heart failure patients with acute myocardial ischemia.
The compound of the following formula
Figure imgf000004_0002
administered intravenously was found to increase myocardial contractile force and heart rate and decrease blood pressure in anesthetized dogs. The compound produced greater hemodynamic effects in dogs with experimentally induced heart failure that than in normal dogs, as reported by C. P. Hsieh, et al, Fed. Proc. Fed. Am. Soc. Exp. Biol., 39, 1106 (1980); and L. E. Roebel, et al, Pharmacologist, 22, 287 (1980).
Summary of the Invention
The present invention is directed to compounds of the formula
,
Figure imgf000004_0003
wherein R is heteroaryl and R' is hydrogen or loweralkyl, and pharmaceutically acceptable salts thereof.
The term "loweralkyl" as used herein refers to straight or branched chain aIkyI radicals containing from 1 to 6 carbon atoms Including but not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, 2-methyIhexyI, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methyIpentyI, 2,2-dimethylpropyl, n-hexyl and the like.
The term "heteroaryl" includes bicyclic heteroaryl such as phthalazine, quinazoline, quinoline, or isoquinoline, and phenyl, either unsubstituted or substituted, naphthyl, thiazole, thiadiazole, thiophene, or pyridyl.
The term "pharmaceutically acceptable salts" includes nontoxic acid addition salts of the compounds of the invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, paimitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and like salts. Also included are metallic salts such as the sodium or potassium salt of the acid.
The present compounds may be administered to warm-blooded animals orally or parenterally. They can generally be administered with a pharmaceutical carrier. The term "pharmaceutical carrier," for the purpose of the present invention, is intended to refer to any medium that is suitable for the preparation of a dosage unit form, and, thus, includes the tablet medium or a pharmaceuticaly acceptable vehicle or solvent such as is ordinarily used in the preparation of intravenous or intramuscular solutions. A pharmaceutical composition containing the compound can be administered to warm-blooded animals in parenteral or oral dosage form. For parenteral administration, amounts of from about 10 to 100 mg/kg per day per patient are useful, with the total dose of up to 0.2 to 2 grams per day being a suitable range for large animals, including humans. A preferred dosage range is from about 1 to 10 grams total daily dosage in a single or divided dose.
For all dosage forms the above exemplified compounds can be placed in capsules, formulated into piIIs, wafers, or tablets in conventional fashion together with pharmaceutical carriers well known in the art. Tablets may be prepared for immediate release of the active compound or they may be made enteric. i.e., whereby the active ingredient is released slowly over a period of several hours from within the intestinal tract.
Detailed Description of the invention
The compounds of the invention can be made by the following described method, the reaction scheme illustrating a representative procedure.
Figure imgf000006_0001
In order to illustrate the manner in which the above compounds may be prepared and the properties of the compounds, reference is made to the following examples, which, however, are not meant to limit or restrict the scope of the invention in any respect.
EXAMPLE 1
4-Propionylpyridine (1)
To a solution of 2.85 M ethylmagnesium bromide (263 mL, 0.75 mol) In ethyl ether (Et2O) (250 mL) was slowly added a solution of 4-cyanopyridine (39 g, 0.375 mol) In Et2O (750 mL). The reaction mixture was warmed at reflux for 12 hours, treated with concentrated H2SO4 (125 mL)/H2O (125 mL), and then washed three times with Et2O (250 mL). The aqueous portion was made basic (pH 9) with 15% NaOH solution and extracted five times with 250 mL portions of Et2O. The combined Et2O extracts were dried (MgSO4), and the solvent was removed under reduced pressure to af ford a brown oi l (48.4 g, 95%) .
Purification by vacuum distillation at 93-97° (2.6 mm) afforded product as a pale yellow oil (25.35 g, 50%), NMR (CDCI3) δ 1.23 (t, 3H, J = 7Hz), 3.00 (q, 2H, J = 7Hz), 7.70 (d, 2H, J = 6 Hz), and 8.78 (d, 2H, J - 6Hz); IR (film) 1695 cm-1.
EXAMPLE 2
4-Propionylpyridine oxime (2)
To a solution of hydroxy lamine hydrochloride (7 g, 0.1 mol) in H2O (40 mL) and 2 N NaOH solution (50 mL) was added the compound 1 (9.46 g, 70 mmol). The reaction mixture was heated to reflux and made homogeneous by the addition of methanol (MeOH) (30 mL). After heating at reflux for 2 hours, the reaction mixture upon cooling gave the compound 2 as a white solid (7.90 g, 75%): mp 141-144°C; NMR (DMS0-d6) δ 1.03 (t, 3H, J = 8Hz), 2.72 (q, 2H, J = 8Hz), 3.34 (bs, 1H), 7.56 (d of d, 2H), and 8.56 (df d, 2H); IR (KBr) 1600 cm-1. EXAMPLE 3
4-PropionyIpyridine oxime tosylate (3)
To the oxlme 2 of Example 2 (5.0 g, 33 mmol) dissolved in pyrldlne (31 mL) was added p-toiuenesulfonyl chloride (7.4 g, 39 mmol) and the reaction mixture stirred at room temperature for 24 hours. Pyridine hydrochloride was removed by filtration and the filtrate concentrated under reduced pressure. The solid obtained was slurried in hexanes, filtered, and air dried to give the compound 3 as a pale peach-colored solid: NMR (CDCI3) δ 1.12 (t, 3H, J = 8Hz), 2.45 (s, 3H), 2.81 (q, 2H, J = 8Hz), and 7.27-7.98 (m, 8H).
EXAMPLE 4
4-(α -aminopropianyl) pyridine dϊhydrochloride (4)
To a solution of KOEt (2.4 g, 28.5 mmol) in absolute ethanol (EtOH) (25 mL) was added a solution of compound 2 (7.9 g, 26 mmol) dissolved in absolute EtOH (40 mL). After stirring at room temperature for 3.5 hours, the reaction mixture was treated with Et2O (400 mL) and filtered. The filtrate was extracted with several portions of 2N HCI and the aqueous extracts concentrated under reduced pressure to give a white solid which was washed with a small amount of cold MeOH and dried under vacuum to give the compound 4 as a white solid (2.64 g, 46%): NMR (DMSO-d6) δ 1.39 (d, 3H, J = 7Hz), 5.13 (m, 1H), 8.15 (d, 2H), 8.52 (m, 1H), and 8.61 (d, 2H).
EXAMPLE (5)
4-Methyl-5-(4 pyrldyl)-2-imidazolone hydrochloride 5
To the compound 4, ( 1 .1 15 g, 5 mmol) dissolved in water (5 mL) was added 6N HCI (0.85 mL, 5 mmol) and a solution of KOCN (0.81 g, 10 mmol) in water (5 mL). After refluxlng for 2 hours, the product was removed by filtration and dried to give the compound 5 as a pale yellow solid (0.47 g, 40%): NMR (DCI ) δ 2.55 (s, 3H), 8.02 (d, 2H, J = 7Hz), and 8.75 (d, 2H, J = 7Hz). Analysis calculated for C9H9N3O.HCI.1 1/3 H2O: C, 45,89; H, 5.17; N, 17.82. Found: C, 45.88; H, 5.42; N, 17.83
The described compounds are active Inotropic or cardiotonic agents. They have been found to increase the contractile force of the heart while having minimal effects on blood pressure and heart rate and can be used in treating patients with diseased hearts for the purpose of increasing cardiac efficiency through a selective increase in the cardiac contractile force.
The cardiotonic activity of the compounds was established using the following test procedure: Male Hartley strain guinea pigs (250-500 g body weight), obtained from Hilltop Lab Animals (Scottdale, PA), were stunned by a blow to the head and the left atria removed and rinsed in a modified Kreb's-Henseleit buffer. The buffer was continuously gassed with 95% oxygen and 5% carbon dioxide and was composed of the following: NaCI, 118 mM; KCI, 4.7 mM; MgSO4, 1.2 mM; KH2PO4, 1.2 mM; CaCI2, 1.25 mM;
NaHCO3, 25 mM; Na2EDTA, 0.03 mM and D-glucose, 11 mM. The left atria were pierced through one end of the atrial appendage by a platinum hook connected to a fine gold chain and pierced at the other end of the appendage by a partially shielded platinum hook fixed to a glass rod.
The glass rod and atrium were suspended in a 30 ml water-jacketed tissue bath containing the Kreb's buffer at 33° C. Also connected to the glass rod was a second shielded platinum wire which was adjusted so that a 3-5 mm length of an unshielded portion of the wire was in contact with the atrium very near to the first shielded wire. Both platinum wires were connected to a Grass CCU1A constant current unit and a current was applled by a Grass S44 stimulator to drive the atrium by means of "point" stimulation. The parameters of stimulation were 1-3 mAmps, 1.5 Hz and 5 msec pulse duration. Each tissue was stretched to an initial resting tension of 1.0 g without further readjustment and washed periodically with fresh Kreb's buffer over a one-hour interval.
Developed tension was measured from a Statham UC-3 force transducer connected to the gold chain and recorded on a Gould 280OS recorder. The force signal was also passed to the A/D converter of a MINC-23 computer where the force signal was derivatlzed to calculate several characteristics of the contractile wave-form.
After the one-hour equilibration period, test compounds were added cumulatively to the bath in small volumes (10-100 ul) at 10-mlnute intervals beginning at concentrations of 10-7 M and increasing by log or 1/2 log units until a concentration of 3 x 10-3 M was reached.
Using the described procedure, the change in tension in milligrams is measured. An increase in tension indicates a greater contractile force. The increase in tension produced by several representative compounds is recorded in the following table:
ISPROTERENOL > 1500 mg, 0.4 uM dose
AMRINONE > 1000 mg, 5 m mol
COMPOUND OF > 1043 mg, 3 m mol EXAMPLE 5

Claims

What is claimed is:
1. A compound of the formula
Figure imgf000011_0002
wherein R is heteroaryl and R1 is hydrogen or loweralkyl, or a pharmaceutically acceptable salt thereof.
2. A compound of Claim 1 where R is pyrldyl and R1 is loweralkyl.
3. A compound of Claim 2 wherein R1 is methyl.
4. A method of treating or relieving the symptoms associated with cardiac disorders in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula
Figure imgf000011_0001
wherein R is heteroaryl and R1 is hydrogen or loweralkyl, or a pharaceutlcally acceptable salt thereof.
5. The method of Claim 4 where R is pyrldyl and R1 is loweralkyl.
6. The method of Claim 5 wherein R1 is methyl.
7. A pharmaceutical composition useful for the treatment of cardiac disorders which comprises a compound of the formula
Figure imgf000012_0001
wherein R is heteroaryl and R1 Is hydrogen or loweralkyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. The composition of Claim 7 where R is pyridyl and R1 is loweralkyl.
9. The composition of Claim 8 wherein R1 is methyl.
PCT/US1984/001854 1983-11-23 1984-11-13 5-heteroarylimidazol-2-ones WO1985002402A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE8585900282T DE3480475D1 (en) 1983-11-23 1984-11-13 5-HETEROARYLIMIDAZOL-2-ONES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/554,498 US4532250A (en) 1983-11-23 1983-11-23 5-Heteroarylimidazol-2-ones having cardiotonic activity
US554,498 1983-11-23

Publications (1)

Publication Number Publication Date
WO1985002402A1 true WO1985002402A1 (en) 1985-06-06

Family

ID=24213587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1984/001854 WO1985002402A1 (en) 1983-11-23 1984-11-13 5-heteroarylimidazol-2-ones

Country Status (8)

Country Link
US (1) US4532250A (en)
EP (1) EP0162102B1 (en)
JP (1) JPS61500494A (en)
AU (1) AU570529B2 (en)
CA (1) CA1258072A (en)
DE (1) DE3480475D1 (en)
IT (1) IT1178243B (en)
WO (1) WO1985002402A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728653A (en) * 1984-05-29 1988-03-01 Pfizer Inc. 6-heteroaryl quinolone inotropic agents
US4740513A (en) * 1985-11-28 1988-04-26 Pfizer Inc. Methyl substituted imidazol-1-yl quinolones
WO2003035638A1 (en) * 2001-10-22 2003-05-01 Tanabe Seiyaku Co., Ltd. 4-imidazolin-2-one compounds
WO2004094404A1 (en) * 2003-04-21 2004-11-04 Tanabe Seiyaku Co., Ltd. 4-imidazolin-2-one compounds
AU2004201666C1 (en) * 2001-10-22 2006-10-12 Tanabe Seiyaku Co., Ltd. 4-Imidazolin-2-one compounds

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
US4698353A (en) * 1985-11-13 1987-10-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic heterocyclic oxazolones
US4728661A (en) * 1985-11-13 1988-03-01 Merrell Dow Pharmaceuticals Inc. Cardiotonic phenyl oxazolones
US4670450A (en) * 1985-11-13 1987-06-02 Merrell Dow Pharmaceuticals Inc. Cardiotonic thiazolones
US4999365A (en) * 1987-03-20 1991-03-12 Merrell Dow Pharmaceuticals Inc. Method of reducing reperfusion injury with imidazol-2-thiones
US4803210A (en) * 1987-05-29 1989-02-07 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic oxazolones
US4743607A (en) * 1987-05-29 1988-05-10 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic imidazolones
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
AR017200A1 (en) 1997-12-23 2001-08-22 Astrazeneca Ab INHIBITING COMPOUNDS OF PROTEIN CINASE C, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL FORMULATIONS THAT UNDERSTAND THEM, USE THE SAME AND PROCESS FOR THE SYNTHESIS OF SUCH COMPOUNDS
SE9800835D0 (en) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2585388A (en) * 1948-11-17 1952-02-12 Lilly Co Eli Preparation of 2-mercaptoimidazoles
US3303199A (en) * 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3488423A (en) * 1965-10-21 1970-01-06 Geigy Chem Corp Process for producing anti-inflammatory effects and compositions
US3538104A (en) * 1969-02-28 1970-11-03 Geigy Chem Corp Pyridyl-2-imidazolones
US3641049A (en) * 1968-10-29 1972-02-08 Jan Olof Sandstrom Imidazoline-2-thiones
US3850944A (en) * 1972-07-29 1974-11-26 Kaken Chemical Co 5-(3'-pyridyl)-2-mercaptoimidazole and derivatives thereof
US4053480A (en) * 1976-04-26 1977-10-11 Velsicol Chemical Corporation 1-thiadiazolyl-5-phenoxy- and phenylthioalkanoyloxy imidazolidinones
EP0059948A1 (en) * 1981-03-05 1982-09-15 Merrell Dow Pharmaceuticals Inc. Novel aroylimidazolones
EP0078546A1 (en) * 1981-11-04 1983-05-11 Merrell Dow Pharmaceuticals Inc. Novel imidazolecarboxamide derivatives
EP0078545A1 (en) * 1981-11-04 1983-05-11 Merrell Dow Pharmaceuticals Inc. Imidazolecarboxylic acid derivatives
US4405635A (en) * 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2585388A (en) * 1948-11-17 1952-02-12 Lilly Co Eli Preparation of 2-mercaptoimidazoles
US3303199A (en) * 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3488423A (en) * 1965-10-21 1970-01-06 Geigy Chem Corp Process for producing anti-inflammatory effects and compositions
US3505350A (en) * 1965-10-21 1970-04-07 Geigy Chem Corp Certain substituted 2-mercaptoimidazole derivatives
US3641049A (en) * 1968-10-29 1972-02-08 Jan Olof Sandstrom Imidazoline-2-thiones
US3538104A (en) * 1969-02-28 1970-11-03 Geigy Chem Corp Pyridyl-2-imidazolones
US3850944A (en) * 1972-07-29 1974-11-26 Kaken Chemical Co 5-(3'-pyridyl)-2-mercaptoimidazole and derivatives thereof
US4053480A (en) * 1976-04-26 1977-10-11 Velsicol Chemical Corporation 1-thiadiazolyl-5-phenoxy- and phenylthioalkanoyloxy imidazolidinones
US4405635A (en) * 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
EP0059948A1 (en) * 1981-03-05 1982-09-15 Merrell Dow Pharmaceuticals Inc. Novel aroylimidazolones
EP0078546A1 (en) * 1981-11-04 1983-05-11 Merrell Dow Pharmaceuticals Inc. Novel imidazolecarboxamide derivatives
EP0078545A1 (en) * 1981-11-04 1983-05-11 Merrell Dow Pharmaceuticals Inc. Imidazolecarboxylic acid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 100, No. 25, June 18, 1984, ISOMURA et al., "Synthesis and Anti-Inflammatory Activity of 2,6-Di-Tert-Butyphenols with Heterocyclic Group at the 4 Position", Abstract No. 209694g, Chem. Pharm. Bull. 1984 32(1), 152-65 *
CHEMICAL ABSTRACTS, Vol. 69, No. 21, November 1968, ISAKA et al., "Synthesis of Biotin", Abstract No. 86911g, YAKUGAKU ZASSHI, 1968 88(4), 422-7 (Japan) *
CHEMICAL ABSTRACTS, Vol. 90, No. 27, 1979 DIVANFARD et al., "Synthesis of 4-Imi-Dazolin-2-Ones via the Birch Reduction of Hydantoins", Abstract No. 90:22893d, J. Heterocycl. Chem. 1978, 15(4), 691 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728653A (en) * 1984-05-29 1988-03-01 Pfizer Inc. 6-heteroaryl quinolone inotropic agents
US4740513A (en) * 1985-11-28 1988-04-26 Pfizer Inc. Methyl substituted imidazol-1-yl quinolones
WO2003035638A1 (en) * 2001-10-22 2003-05-01 Tanabe Seiyaku Co., Ltd. 4-imidazolin-2-one compounds
AU2004201666C1 (en) * 2001-10-22 2006-10-12 Tanabe Seiyaku Co., Ltd. 4-Imidazolin-2-one compounds
KR100742058B1 (en) * 2001-10-22 2007-07-23 다나베 세이야꾸 가부시키가이샤 4-imidazolin-2-one compounds
WO2004094404A1 (en) * 2003-04-21 2004-11-04 Tanabe Seiyaku Co., Ltd. 4-imidazolin-2-one compounds

Also Published As

Publication number Publication date
EP0162102B1 (en) 1989-11-15
CA1258072A (en) 1989-08-01
EP0162102A4 (en) 1986-03-18
JPH0572390B2 (en) 1993-10-12
IT8449177A1 (en) 1986-05-16
EP0162102A1 (en) 1985-11-27
DE3480475D1 (en) 1989-12-21
JPS61500494A (en) 1986-03-20
IT8449177A0 (en) 1984-11-16
US4532250A (en) 1985-07-30
AU570529B2 (en) 1988-03-17
IT1178243B (en) 1987-09-09
AU3678384A (en) 1985-06-13

Similar Documents

Publication Publication Date Title
AU570529B2 (en) 5-heteroarylimidazol-2-ones
EP0233051B1 (en) Antiarrhythmic agents
JPS63502031A (en) Hydroxy and aminothiozolyl-benzodiazinone compounds, cardiotonic compositions containing the same, and uses thereof
AU568087B2 (en) Heteroaryl substituted aminomethyl benzene derivatives
EP0539153B1 (en) Acridine derivative as therapeutic agent
KR850001858B1 (en) Process for preparing 2-guanidino-4-heteroarylthiazoles
US4921856A (en) Dihydropyridazinone derivatives, a process for their preparation and pharmaceutical preparations containing these compounds
JP3083544B2 (en) Drugs to prevent or treat heart disease
JPS6140286A (en) 1,6_naphthyridine_2(1h)_one useful as cardiac stimulant
SU1087519A1 (en) Salts of derivatives of 1,2,4-oxadiazolin-5-one having properties of cardiovascular stimulators
NO165635B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE QUINOLINE DERIVATIVES.
GB2095240A (en) Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
JPH01500596A (en) Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic drugs
OA12256A (en) Sodium-hydrogen exchanger type 1 inhibitor (NHE-1).
US4657919A (en) Pyridone esters as inotropic agents
US4555517A (en) Pyridone esters as inotropic agents
GB2066251A (en) 3-acylamino-s-(pyridinyl)-2(1h)-pyridinones
PL92078B1 (en)
US4486431A (en) Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones
IE53586B1 (en) Triazole gastric anti-secretory agents
US5475028A (en) 2-aminoethanesulfonic acid zinc complex
US3426034A (en) Omega-phenyl-omega-pyridyl alkylamine derivatives
EP0405784A1 (en) Novel benzisoquinoline derivatives
JPS6348273A (en) Quinolone cardiac
CA2223388A1 (en) Diheterocyclic acrylonitriles as smooth muscle cell proliferation inhibitors

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): CH DE FR GB SE

WWE Wipo information: entry into national phase

Ref document number: 1985900282

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985900282

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1985900282

Country of ref document: EP